D. Western Therapeutics Institute, Inc. (TYO:4576)
Japan flag Japan · Delayed Price · Currency is JPY
117.00
-2.00 (-1.68%)
Jul 25, 2025, 3:30 PM JST
-1.68%
Market Cap5.30B
Revenue (ttm)463.52M
Net Income (ttm)-1.12B
Shares Out45.28M
EPS (ttm)-29.40
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume792,500
Average Volume862,110
Open119.00
Previous Close119.00
Day's Range116.00 - 120.00
52-Week Range60.00 - 254.00
Beta-0.06
RSI41.19
Earnings DateAug 14, 2025

About TYO:4576

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 21
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4576
Full Company Profile

Financial Performance

In 2024, TYO:4576's revenue was 471.00 million, an increase of 10.05% compared to the previous year's 428.00 million. Losses were -1.29 billion, 58.9% more than in 2023.

Financial Statements

News

There is no news available yet.